Monday, April 10, 2006


Viral Hepatitis C - Indenix is Nearing Phase III for Valopicitabine


Indenix is Nearing Phase III for Valopicitabine
It is always good to see progress with alternatives to current medical therapy for HCV. Even though companies that are working on solutions to be used with interferon are not really offering anything groundbreaking or revolutionary, it does continue the...

SCH 503034 Jumps on the Fast Track
Schering-Plough's oral HCV protease inhibitor, SCH 503034, is in phase II trials, and may make for a better combination with Peg-intron. Check-in with us regularly, as we will be keeping close tabs on this development....

Fatty Liver
Title: Fatty LiverCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 8/29/2005

Hepatitis C Patients Taxing Medical System
Title: Hepatitis C Patients Taxing Medical SystemCategory: Health NewsCreated: 12/31/2005 1:59:00 AMLast Editorial Review: 12/31/2005 1:58:37 AM